|
82 |
The most common challenges with a cleanroom
|
sureAssist |
2024-12-26 |
613 |
|
81 |
The Real Cost Of Poor Quality — And What You Should Do About It
|
sureAssist |
2024-12-26 |
567 |
|
80 |
Draft Q&A Guidance Offers Roadmap For Biosimilar Post-approval Changes
|
sureAssist |
2024-12-26 |
551 |
|
79 |
10 points on how the FDA's CDER monitors the Quality of Medicinal Products
|
sureAssist |
2024-12-26 |
528 |
|
78 |
The difference between an ISO 17025 certified laboratory and an ISO 9001 one
|
sureAssist |
2024-12-26 |
523 |
|
77 |
This Week at FDA: Updated guidance on denying inspections and biosimilar interchangeability
|
sureAssist |
2024-12-26 |
672 |
|
76 |
Are Annex 1's CCS Requirements Still Challenging You?
|
sureAssist |
2024-12-26 |
873 |
|
75 |
Requalification of an Automatic Inspection System (AVI)
|
sureAssist |
2024-12-26 |
524 |
|
74 |
EMA: Update of the Annex to the Excipients Guideline
|
sureAssist |
2024-12-26 |
536 |
|
73 |
New FDA Draft Guidance: Data Integrity For In Vivo Bioavailability And Bioequivalence Studies
|
sureAssist |
2024-12-26 |
618 |
